Drugs that contain Ketorolac Tromethamine

1. List of Acular Ls drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 3 months from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 9 months from now)

US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2027

(4 years from now)

Market Authorisation Date: 30 May, 2003

Treatment: A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging; A method of treating or preventing ocular pain in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's patent expiration?
More Information on Dosage

2. List of Acuvail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7842714 ALLERGAN Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(1 year, 6 months from now)

US9192571 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Mar, 2028

(5 years from now)

US8512717 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Mar, 2028

(5 years from now)

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic